242 related articles for article (PubMed ID: 36107387)
21. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.
Tong R; Feng X; Sun J; Ling Z; Wang J; Li S; Yang B; Deng J; He G; Wu J
Small; 2024 May; 20(21):e2307273. PubMed ID: 38102096
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
23. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
[TBL] [Abstract][Full Text] [Related]
24. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
25. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
26. Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1α to inhibit apoptosis.
Gao Z; Wang D; Yang J; Li M; Ling C; Lv D; Cao Y; Chen Z; Shi C; Shen H; Tang Y
Biomed Pharmacother; 2023 Jul; 163():114750. PubMed ID: 37087978
[TBL] [Abstract][Full Text] [Related]
27. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
28. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
[TBL] [Abstract][Full Text] [Related]
29. A novel sesquiterpene lactone fraction from Eupatorium chinense L. suppresses hepatocellular carcinoma growth by triggering ferritinophagy and mitochondrial damage.
Zhu ZH; Xu XT; Shen CJ; Yuan JT; Lou SY; Ma XL; Chen X; Yang B; Zhao HJ
Phytomedicine; 2023 Apr; 112():154671. PubMed ID: 36773432
[TBL] [Abstract][Full Text] [Related]
30. Carnosic acid protects against ferroptosis in PC12 cells exposed to erastin through activation of Nrf2 pathway.
Cheng J; Xu T; Xun C; Guo H; Cao R; Gao S; Sheng W
Life Sci; 2021 Feb; 266():118905. PubMed ID: 33333051
[TBL] [Abstract][Full Text] [Related]
31. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
[TBL] [Abstract][Full Text] [Related]
32. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
Li X; Li Y; Lian P; Lv Q; Liu F
Hum Exp Toxicol; 2023; 42():9603271221142818. PubMed ID: 36786348
[TBL] [Abstract][Full Text] [Related]
33. SNRPB promotes the progression of hepatocellular carcinoma via regulating cell cycle, oxidative stress, and ferroptosis.
Wang X; Zhang H; Guo Z; Wang J; Lu C; Wang J; Jin R; Mo Z
Aging (Albany NY); 2024 Jan; 16(1):348-366. PubMed ID: 38189879
[TBL] [Abstract][Full Text] [Related]
34. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial ROS driven by NOX4 upregulation promotes hepatocellular carcinoma cell survival after incomplete radiofrequency ablation by inducing of mitophagy via Nrf2/PINK1.
Peng C; Li X; Ao F; Li T; Guo J; Liu J; Zhang X; Gu J; Mao J; Zhou B
J Transl Med; 2023 Mar; 21(1):218. PubMed ID: 36964576
[TBL] [Abstract][Full Text] [Related]
36. Role of ferroptosis in hepatocellular carcinoma.
Nie J; Lin B; Zhou M; Wu L; Zheng T
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2329-2337. PubMed ID: 30167889
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma.
Liu MR; Shi C; Song QY; Kang MJ; Jiang X; Liu H; Pei DS
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37695069
[TBL] [Abstract][Full Text] [Related]
38. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
Chang K; Chen Y; Zhang X; Zhang W; Xu N; Zeng B; Wang Y; Feng T; Dai B; Xu F; Ye D; Wang C
Cancer Res; 2023 Dec; 83(23):3940-3955. PubMed ID: 37713596
[TBL] [Abstract][Full Text] [Related]
39. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
[TBL] [Abstract][Full Text] [Related]
40. A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.
Lai Y; Lu N; Luo S; Wang H; Zhang P
J Med Chem; 2022 Oct; 65(19):13041-13051. PubMed ID: 36134739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
